Fluidity ONE-W Serum

Fluidity ONE-W Serum can accurately detect and characterise the binding affinity of antibodies to virus proteins directly in human serum.

Fluidity ONE-W Serum

Fluidity ONE-W Serum can accurately detect and characterise the binding affinity of antibodies to virus proteins directly in human serum.

Manufacturer Fluidic Analytics
Product Series Fluidity One
Measurement principle Microfluidic Diffusional Sizing (MDS)
Application Biomolecular Interactions, Nano Particle Size, Protein Conformation, Protein Interactions & Binding Affinity
Size range (hydrodynamic radius)1 - 20 nm
Molecular Weight range1.4 kDa - 14 MDa
Sample requirement5 µL
Sensitivity1nM Alexa Fluor 647

Product Overview

Fluidity One-W Serum is a novel in-solution immunoassay platform that allows researchers to characterise and quantify antigen-antibody interactions directly in minimally diluted serum.

This new instrument provides quantitative insights into antibody affinity and concentration directly in patient serum that cannot easily be obtained with traditional antibody tests such as ELISA which combine affinity and concentration into a single, less-precise measure known as titer.

The ability to quantify both affinity and concentration allows for a better understanding of the in vivo immune response than titre alone. It helps to readily distinguish between large numbers of weak-binding antibodies and small numbers of strong-binding antibodies. In-solution measurements do not rely on attaching antigens to surfaces and thus eliminate the many drawbacks of immobilised assays including non-specific binding and binding artifacts.

Fluidity One‑W Serum was developed in response to the COVID‑19 pandemic. It enables comprehensive profiling of the antibody response to SARS‑CoV‑2 on the basis of affinity.




Fluidity One-W Serum

  • Characterisation of protein interactions in solution using microfluidic diffusional sizing (MDS)
  • Ability to measure in complex backgrounds such as minimally diluted serum
  • No binding artifacts or non-specific binding, no surface-constraints
  • Independent determination of antibody concentration and affinity for a comprehensive immune response assessment
  • Easy-to-use interface and consumable management
  • Disposable single use chips and contained waste minimise risk of cross contamination


Quantify protein interactions
Determine antibody affinity (antibody binding strength) and concentration directly in patient serum for a comprehensive immune response assessment.

Fingerprints of affinity and concentration in real time
Independent determination of antibody affinity and concentration for comprehensive immune response assessments in real time.

In-solution measurements in complex backgrounds
Elimination of non-specific binding and other binding artifacts for accurate characterisation of protein interactions in biological mixtures such as crude lysates, plasma without surface constraints or binding artifacts.

Accurate solution phase affinity profiling of a SARS-CoV-2 antibody in serum
This application note demonstrates the use of MDS technology for in-depth analysis of the humoral immune response against SARS-CoV-2 to support the development of reliable antibody tests and vaccines in the fight against the COVID-19 pandemic.

Product Enquiry


If you would like to enquire about this product, fill out this form and one of our product specialists will contact you shortly.
If you need help in the operation or repair of an instrument then please contact the Customer Help Centre directly.

Please note, product enquiries are only applicable to Australia, New Zealand, Papua New Guinea and Fiji

    Or call us instead at (02) 9541 3500